BioInvent to Present Clinical Data from its Two Leading Assets at ASCO 2024 - Seite 2

Details of the abstracts to be presented:

Title: 19-B1-1808-01, a Phase 1/2a Clinical Trial of BI-1808, a Tumor Necrosis Factor Receptor 2 (TNFR2) Blocker/Depleter with or without Pembrolizumab
Abstract Number: 2641
Session: Developmental Therapeutics - Immunotherapy
Date: June 1, 2024
Time: 9:00 AM - 12:00 PM CDT

Title: Phase 1/2a Clinical Trial of BI-1206, an Anti-CD32b (FCgammaRIIB) Antibody, in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD-1/PD-L1
Abstract Number: 2593
Session: Developmental Therapeutics - Immunotherapy
Date: June 1, 2024
Time: 9:00 AM-4:00 PM CDT

About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on the social media platform X: @BioInvent.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

For further information, please contact:
Cecilia Hofvander, Senior Director Investor Relations
Phone: [phone]
Email: [e-mail]

BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: [phone]
www.bioinvent.com

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Attachments

BioInvent to Present Clinical Data from its two leading assets at ASCO 2024

SOURCE: BioInvent International

View the original press release on accesswire.com


The BioInvent International Stock at the time of publication of the news with a raise of +0,61 % to 1,982SEK on Frankfurt stock exchange (24. April 2024, 08:05 Uhr).